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Case Report 
Large Retrosternal Parathyroid Carcinoma with
Primary Hyperparathyroidism
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Parathyroid carcinoma is an uncommon cause of parathyroid hormone (PTH)-dependent hypercalcaemia,
accounting for less than 1% of all cases of hyperparathyroidism. Parathyroid carcinoma is an indolent
tumour with rather low malignant potential. Consideration of parathyroid carcinoma in the differential
diagnosis of hypercalcaemic disorders is important because the morbidity and mortality are substantial
and the best prognosis is associated with early recognition and surgical resection. Clinical indicators
favouring parathyroid carcinoma over benign disease include markedly raised serum calcium levels, PTH
and alkaline phosphatase. A palpable neck mass with both kidney and skeletal manifestations also give a
high index of suspicion of parathyroid carcinoma. Histopathology alone is not sufficient to diagnose
parathyroid cancer; it has to be correlated with the clinical findings. The initial and most effective treatment
for parathyroid carcinoma is complete resection of the primary lesion, and repeated operations for recurrence
are useful. The prognosis of parathyroid carcinomas is quite variable; 5-year survival rates vary from 40%
to 86%, while the 10-year survival rate is approximately 49%. We report a case of parathyroid carcinoma
occurring in a 55-year-old woman who presented with bone pain and hypercalcaemia. [Asian J Surg
2007;30(4):286–9]
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Introduction
Parathyroid carcinoma is an uncommon endocrine malig-
nancy. In patients treated for hyperparathyroidism, the
reported incidence of cancer is less than 1%.1,2 Clinically,
patients with parathyroid carcinoma present with symp-
tomatic hypercalcaemia, osteolytic bone changes, and
renal impairment more often than patients with benign
forms of hyperparathyroidism.2,3 Consideration of parathy-
roid carcinoma in the differential diagnosis of hypercal-
caemic disorders is important because the morbidity and
mortality are substantial and the best prognosis is associ-
ated with early recognition and surgical resection.4 A cancer
diagnosis may also require repeat operative procedures
for recurrence as the best mode of palliative treatment.
The controversies regarding parathyroid cancer are related
to the establishment of a firm diagnosis when the macro-
scopic and microscopic findings are ambiguous. The so-
called classical criteria of malignancy (trabecular pattern,
fibrous bands, mitotic figures, and capsular and vascular
invasion) stated by Schantz and Castleman in their study
of 70 cases of parathyroid cancer have provided useful
guidelines.5 However, it is also well documented that
sometimes these criteria are unreliable and only by clinical
observation and the presence of recurrence may the diag-
nosis be finally established.1,4,6 In equivocal cases, a close
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follow-up is recommended. We report a case of parathy-
roid carcinoma in a 55-year-old woman who presented
with bone pain and hypercalcaemia.
Case report
A 55-year-old woman complained of headache, blurring
of vision, vomiting and bone pain that was marked in the
long bones. There was also polyuria, nocturia, loss of
appetite and loss of weight. There was no similar complaint
observed in the family members. General examination
revealed cachexia. Neck examination showed an anterior
neck swelling that measured 2.0 × 2.0 cm, and which was
firm in consistency and non-tender.
A computed tomography (CT) scan of the head showed
multiple osteolytic lesions with a pepperpot skull, and
large brown tumours at the right frontal and right
petrous apex bone. There was no tumour identified at the
jaw region. Skeletal survey showed features consistent
with hyperparathyroidism. Serum calcium and parathy-
roid hormone (PTH) levels were raised, 5.75 mmol/L and
> 26,325 pmol/L (normal, 5–50 pmol/L), respectively.
Alkaline phosphatase was 1,220 U/L (normal, 32–104 U/L).
Ultrasound of the neck revealed a large mass, located pos-
terior and lateral to the left thyroid lobe, which was solid
and cystic in nature (Figure 1).
A parathyroid carcinoma was suspected preoperatively
due to the high calcium level and multiple complications.
Complete surgical excision of the left superior parathy-
roid mass was done. Intraoperatively, there was a large left
superior parathyroid extending retrosternally into the
posterior mediastinum. The parathyroid appeared well
encapsulated and was separated from the thyroid gland.
Grossly, the mass was brownish and solid-cystic in nature,
measuring 8.5×4.5×3.0 cm, and weighing 58.7 g. Histologi-
cally, the tumour mass was composed of nests and trabec-
ulae of neoplastic chief cells interspersed with thin and
thick fibrous bands (Figure 2). These neoplastic cells
exhibited hyperchromatic, mildly pleomorphic nuclei,
with scattered mitoses (2 per 10 high power field) (Figure 3).
Capsular and vascular invasion were also noted (Figures 2
and 4). The adjacent thyroid gland and the surgical margins
were free from tumour. Immunohistochemically, these
neoplastic cells were positive for cytokeratin, neuron spe-
cific enolase and chromogranin, while Ki-67 showed 5%
positivity and cyclin D1 showed strong diffuse positivity.
At 6 months follow-up, her serum calcium was 2.25 mmol/L
and serum PTH was 9.9 pmol/L. There were neither features
of local recurrence nor distant metastasis found.
Figure 1. A large solid and cystic mass, located posterior and lat-
eral to the left lobe of the thyroid.
Figure 2. Nests and trabeculae of malignant parathyroid cells,
with evidence of capsular invasion (haematoxylin & eosin; original
magnification, 100×).
Figure 3. High power view of parathyroid carcinoma cells, exhibit-
ing only mild pleomorphism with presence of mitotic activity
(haematoxylin & eosin; original magnification, 200×).
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Discussion
Parathyroid carcinoma is an uncommon cause of PTH-
dependent hypercalcaemia, with approximately 400 cases
reported in the literature from 1930 to 2001.7 In most
series, this entity accounts for less than 1% of patients with
primary hyperparathyroidism.2,4,5 However, this disease
may be somewhat more common in Japan than in Western
countries, accounting for 5% of patients with primary
hyperparathyroidism.8 Parathyroid carcinoma is an indo-
lent tumour with rather low malignant potential. It tends
to recur locally at the operative site and spread to contigu-
ous structures in the neck. Metastases occur late in the
course of the disease with spread via both lymphatic and
haematogenous routes. Cervical nodes (30%) and lung
(40%) are involved most commonly, followed by liver (10%).
Occasional involvement of bone, pleura, pericardium, and
pancreas have also been reported.7
Several presenting features of a patient with primary
hyperparathyroidism suggest a malignant rather than
benign aetiology. Markedly raised serum calcium levels,
high levels of parathyroid hormone and alkaline phos-
phatase, and elevated levels of α- and β-subunits of human
chorionic gonadotrophin are among the notable findings
of parathyroid carcinoma. A palpable neck mass has been
reported in 30–76% of patients with parathyroid car-
cinoma.2,3 This important clinical finding constitutes
another striking difference between benign and malig-
nant parathyroid disease, as a palpable mass is distinctly
unusual in primary hyperparathyroidism.3
The kidney and skeleton are the main target sites of the
PTH effect, and they are affected with greater frequency
and severity in parathyroid carcinoma than in benign
lesions.2,4,8 Kidney manifestations such as nephrolithia-
sis, nephrocalcinosis, impaired glomerular filtration, and
skeletal lesions in the form of bone pain and pathological
fractures are common features of parathyroid cancer.4
Radiologically, parathyroid carcinoma often shows signs
of hyperparathyroid skeletal disease such as osteitis fibrosa
cystica, subperiosteal bone resorption, “salt and pepper”
skull, absent lamina dura and diffuse spinal osteopaenia.
In contrast, patients with benign primary hyperparathy-
roidism rarely have skeletal complaints and specific radio-
logical signs are found in less than 5%. It is also important
to note the high incidence of concomitant bone and stone
disease that occurs in parathyroid cancer, whereas simul-
taneous renal and overt skeletal involvement is distinctly
unusual in primary hyperparathyroidism.7 In addition to
the kidneys and skeleton, other manifestations such as
recurrent severe pancreatitis, peptic ulcer disease, and
anaemia also occur with greater frequency in patients
with malignant disease than in those with benign primary
hyperparathyroidism.7
Intraoperatively, parathyroid carcinomas are frequently
lobulated and firm-to-stony hard; while benign adenomas
are usually soft, round or oval in shape, and reddish-
brown in colour. About 50% of parathyroid carcinomas
are surrounded by a dense, fibrous, grayish-white capsule
that adheres to adjacent tissues and makes the tumour
difficult to separate from contiguous structures. Gross
infiltration of adjacent thyroid, nerve, muscle or oesoph-
agus, or obvious cervical node metastases may also be
present. However, any one or all of these operative find-
ings may be absent, and examination of frozen sections is
of little value in distinguishing benign from malignant
disease.7
Histopathological distinction between benign and
malignant parathyroid tumours is difficult. Shantz and
Castleman in 1973 established a set of criteria for the
pathological diagnosis of malignancy, notably: (1) uniform
sheets of (usually chief) cells arranged in a lobular pattern
separated by dense fibrous trabeculae; (2) capsular or vas-
cular invasion; (3) mitotic figures within tumour parenchy-
mal cells.5 However, none of these are pathognomonic of
carcinoma, since features like dense fibrous trabeculae,
trabecular growth pattern, mitoses and capsular invasion
have also been found in parathyroid adenomas.3 In another
study, Bondeson et al considered that cellular atypia,
including nuclear pleomorphism and enlargement and
macronucleoli, are associated with a greater likelihood of
Figure 4. Vascular invasion by parathyroid carcinoma cells
(haematoxylin & eosin; original magnification, 200×).
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malignancy.9 Capsular and vascular invasion appear to
correlate best with subsequent tumour recurrence.
Hyperparathyroidism-jaw tumour syndrome (HPT-JT
syndrome) is a rare autosomal dominant disorder charac-
terized by parathyroid adenoma or carcinoma, fibro-osseous
lesions of the mandible and maxilla, and renal cysts and
tumours. However, in some families, parathyroid tumours
may be the sole manifestation; this has been referred to as
familial isolated hyperparathyroidism. The gene causing
HPT-JT, referred to as HRPT2, is located on chromosome
1q31.2 and consists of 17 exons that encode a 531-amino
acid protein named parafibromin.10 We strongly suspect
that our patient may have the abovementioned syndrome,
and genetic counselling is recommended.
Therapeutically, the initial and most effective treat-
ment for parathyroid carcinoma is complete resection of
the primary lesion at the time of the initial operation
when extensive local invasion and distant metastases are
less likely.2,3 The situation is more complex when diagno-
sis is made postoperatively based on histopathology. This
is particularly so in view of the controversy that exists
regarding the histopathological diagnosis of parathyroid
carcinoma. It has been suggested that if the gross charac-
teristics of the lesion were typical of a parathyroid carci-
noma and the subsequent pathology is aggressive with
extensive vascular or capsular invasion or if the patient
remains hypercalcaemic, then re-exploration of the neck
is indicated. If no clinical features are present, and diag-
nosis was made only on the basis of microscopic char-
acteristics, then immediate re-operation may not be
necessary, as simple resection of the tumour is often cura-
tive. However, such a patient must be observed carefully
with frequent measurements of PTH and serum calcium
levels.7
The management of recurrent or metastatic parathy-
roid carcinoma is primarily surgical, as even very small
tumour deposits may produce sufficient PTH to cause
severe hypercalcaemia.2,4,8 Studies on the benefits of radi-
ation and chemotherapy have shown widely varying
results, from disappointing to hopeful.4–6,11
When parathyroid carcinoma has become widely dis-
seminated and surgical resection is no longer effective,
the prognosis is poor. The therapeutic goal at this point
is to control the hypercalcaemia, which may be difficult
due to the extremely elevated PTH levels. Bisphosphonates,
plicamycin, calcitonin, gallium, calcimimetics, WR-2721
and octreotide are among the drugs currently used.7
The prognosis of parathyroid carcinoma is quite vari-
able. Early recognition and complete resection at the time
of initial surgery carries the best prognosis. The average
time between surgery and the first recurrence is approxi-
mately 3 years, although intervals of up to 20 years have
been reported. Once the tumour recurs, complete cure is
unlikely, although prolonged survival is still common with
palliative surgery. Five-year survival rates vary from 40% to
86%, while the 10-year survival rate is approximately 49%.12
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